4.57  0.07 (1.56%)		10-24 16:00
Open: 4.55 High: 4.66 Volume: 496,571		Pre. Close: 4.5 Low: 4.45 Market Cap: 150(M)

Short term
Mid term
Targets	6-month :	7.4	1-year :	8.64
Resists	First :	6.34	Second :	7.4
Pivot price	4.77
Supports	First :	3.57	Second :	1.86
MAs	MA(5) :	4.69	MA(20) :	4.79
	MA(100) :	2.15	MA(250) :	2.55
MACD	MACD :	0.4	Signal :	0.6
%K %D	K(14,3) :	19.3	D(3) :	30.4
RSI	RSI(14): 57.7
52-week	High :	8.32	Low :	0.87

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ PEPG ] has closed above bottom band by 20.5%. Bollinger Bands are 37.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	4.66 - 4.69	4.69 - 4.72
Low:	4.39 - 4.42	4.42 - 4.45
Close:	4.52 - 4.57	4.57 - 4.61

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Sun, 19 Oct 2025
Bronstein, Gewirtz & Grossman, LLC Encourages PepGen Inc. (PEPG) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Tue, 07 Oct 2025
PepGen: DMD Discontinued, Ways To Go With DM1 (NASDAQ:PEPG) - Seeking Alpha

Wed, 01 Oct 2025
PepGen Inc. Stock (PEPG) Opinions on Recent Insider Buying and Offering Closure - Quiver Quantitative

Wed, 01 Oct 2025
Major Stakeholder Makes Bold Move with PepGen Inc. Stock Purchase! - TipRanks

Tue, 30 Sep 2025
PepGen Inc. (PEPG) Rating Upgraded With 135% Upside on FREEDOM Data - Yahoo Finance

Fri, 26 Sep 2025
PepGen (PEPG) Skyrockets 121% on Stellar Experimental Treatment Trial Results - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	69 (M)
Shares Float	19 (M)
Held by Insiders	0.1 (%)
Held by Institutions	59.5 (%)
Shares Short	5,170 (K)
Shares Short P.Month	1,130 (K)

EPS	-2.97
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.17
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-43.5 %
Return on Equity (ttm)	-85.7 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.48
Qtrly Earnings Growth	0 %
Operating Cash Flow	-90 (M)
Levered Free Cash Flow	-56 (M)

PE Ratio	-1.55
PEG Ratio	0
Price to Book value	2.1
Price to Sales	0
Price to Cash Flow	-3.49

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.